RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 No Significant Improvement in Vasospasm-Related Morbidity or All-Cause Mortality with Clazosentan after aSAH
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 1
SP 14
OP 15
DO 10.1177/155989771101006
UL http://mdc.sagepub.com/content/11/1/14.abstract
AB Results from the Clazosentan in Reducing Vasospam-Related Morbidity and Mortality in Adult Patients with Aneurysmal Subarachnoid Hemorrhage Treated By Surgical Clipping [CONSCIOUS-2; NCT00558311] study indicate that the use of the endothelin receptor antagonist clazosentan does not significantly improve vasospasm-related morbidity or all-cause mortality after aneurysmal subarachnoid hemorrhage.